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Mitral regurgitation (MR) has previously been classiﬁed into rheumatic, primary, and secondary MR according to the underlying
diseaseprocess.Carpentier’s/Duranfunctionalclassiﬁcationsareaptindescribingthemechanism(s)ofMR.Modernmanagement
of MR, however, depends primarily on the severity of MR, status of the left ventricular function, and the presence or absence of
symptoms, hence the need for a management-oriented classiﬁcation of MR. In this paper we describe a classiﬁcation of MR into
4 phases according to LV function: phase I = MR with normal left ventricle, phase II = MR with normal ejection fraction (EF)
and indirect signs of LV dysfunction such as pulmonary hypertension and/or recent onset atrial ﬁbrillation, phase III = EF ≥30%–
<50% and/or mild to moderate LV dilatation (ESID 40–54mm), and phase IV = EF < 30% and/or severe LV dilatation (ESDID
≥ 55mm). Each phase is further subdivided into three stages: stage “A” with an eﬀective regurgitant oriﬁce (ERO) < 20mm, stage
“B” with an ERO = 20–39mm, and stage “C” with an ERO ≥ 40mm. Evidence-based indications and outcome of intervention for
MR will also be discussed.
1.Introduction
In the Strong Heart Study, moderate and severe mitral
regurgitation (MR) was found in 1.9 and 0.2 percent of the
population, respectively [1]. With an ageing population in
whom the prevalence of MR is rising [2], MR will remain
a common and growing clinical entity. Mitral regurgitation
(MR) is caused by diseases aﬀecting the mitral apparatus,
including myxomatous degeneration (mitral valve prolapse),
rheumatic heart disease, and infective endocarditis, or by
changes in the size or shape of the left ventricle (LV) that
precludeeﬀectiveleaﬂetcoaptationofagrosslynormalvalve,
often secondary to underlying ischemic or nonischemic car-
diomyopathy [3, 4]. After an initial phase of hemodynamic
compensation for volume overload, patients experience a
slow and progressive decline in exercise tolerance. The onset
of symptoms is often insidious as it develops over 5- to 10-
year period [3–5]. Theimpacton survivalcanbe sodramatic
that severe MR due to ﬂail leaﬂets has been associated with
an annual mortality of up to 7% [5, 6]. Mortality is further
exaggerated in patients with signiﬁcant symptoms and/or
impaired left ventricular systolic function.
Compared to medical therapy, mitral valve repair or
replacement is associated with superior functional status,
as well as better short- and long-term survival, especially
if performed before the development of persistent atrial
ﬁbrillation, pulmonary hypertension, LV dysfunction, or
LV enlargement. Surgical intervention for severe MR is
indicated in the setting of symptoms, LV systolic dysfunction
(ejection fraction <50%), signiﬁcant LV dilation (end-
systolic dimension ≥40mm), pulmonary arterial hyperten-
sion (pulmonary arterial systolic pressure >50mm Hg at
rest or >60mm Hg with exercise), or new-onset atrial
ﬁbrillation [3–6]. Current guidelines support consideration
for “prophylactic” mitral valve repair in asymptomatic
patients with severe MR, even in the absence of signiﬁcant
LV dilation or systolic dysfunction, if successful repair is
expected in more than 90% of the cases [3, 7].2 ISRN Cardiology
2. CurrentClassiﬁcations of MR
Classiﬁcation of mitral valve regurgitation has been based
on anatomical or etiological basis [3, 4]. Two schemes of
anatomical classiﬁcation have evolved; Carpentier’s classiﬁ-
cation[8]labelstheanterolateral,middle,andposteromedial
cusps of the posterior leaﬂet as P1, P2, and P3, respectively;
the anterior leaﬂet carries corresponding labels of A1, A2,
and A3. Kumar et al. [9] divide the valve into anterolateral
and posteromedial halves. The middle cusp of the posterior
leaﬂet is divided further into anterolateral (PM1) and
posteromedial sections (PM2).
Etiologically [5], MR has previously been classiﬁed as
follows.
(1) Primary MR that is due to organic diseases aﬀecting
the mitral apparatus including myxomatous degen-
eration [mitral valve prolapse], rheumatic heart
disease, and leaﬂet perforation or other sequelae
heart infective endocarditis.
(2) Secondary, otherwise known as functional, MR
which is a sequelae of alteration LV size or shape
(due to underlying ischemic, nonischemic, or hyper-
trophic cardiomyopathy).
These classiﬁcations, together with Carpentier’s func-
tional analysis of mitral valve motion [3] allowed the devel-
opment of a common language between the physician who
performs non-invasive imaging and the operating surgeon,
which is the basic foundation for planning successful repair.
3. Management-Oriented Classiﬁcation of MR
None of the classiﬁcation schemes mentioned previously,
however, correlates the severity of MR, the status of the left
ventricle, and the patients’ symptoms, which are the primary
determinants of the nature and the timing of intervention
in patients with MR [3–6]. Moreover, recent introduction of
low-risk, less invasive surgical, and percutaneous techniques
for controlling MR [10] poised to expand the indications
for intervention in patients with MR and highlight the need
for a management-oriented classiﬁcation for MR. In this
paper, we provide such classiﬁcation and discuss current
indicationsandoutcomeofinterventionforMR.Wepropose
anovelclassiﬁcationforMRbysubdividingMRinto4phases
according to LV function: phase I = MR with normal left
ventricle, phase II = MR with normal ejection fraction (EF)
and indirect signs of LV dysfunction such as pulmonary
hypertension and/or recent onset atrial ﬁbrillation, phase
III = EF ≥ 30% < 50% and/or mild to moderate LV
dilatation (ESID 40–54mm), and phase IV = EF < 30%
and/or severe LV dilatation (ESDID ≥ 55mm). Each phase is
further subdivided according to the severity of MR into three
stages: stage “A” with an eﬀective regurgitant oriﬁce (ERO) <
20mm, stage “B” with an ERO = 20–39mm, and stage “C”
with an ERO ≥ 40mm (see Table 1).
4. Indications of Surgery for
MitralRegurgitation
Mitral valve repair or replacement with chordal preservation
is a class “I” indication in patients with symptomatic (NYHA
class II-IV) severe mitral valve regurgitation [3]. Man-
agement of severe primary MR in asymptomatic patients
with preserved LV function and end-systolic dimension
<40mm stage remains controversial [3, 4, 7]. Enriquez-
Sarano et al. reported worse outcome in this category of
patients if treated medically [5], as opposed to early surgical
repair, whereas Rosenhek et al. recommended that close
followup of asymptomatic patients with severe degenerative
MR until symptoms or LV dilation occurs [11] (watchful
waiting strategy) may have a better long-term outcome.
Many experts, however, believe that in order to preserve
LV function and prevent sequels of severe MR, MV repair
may be oﬀered to asymptomatic patients with chronic
severe primary MR with normal LV dimensions and EF
[3, 4, 7]. Despite the absence of randomized trials testing
this approach, there is a trend towards considering earlier
intervention, and ACC/AHA guidelines [3] classify mitral
valve repair in asymptomatic severe MR with preserved EF
and end-systolic dimension <40mm as Class IIa indication
(Level “B” Evidence) if the likelihood of successful mitral
valve repair exceeds 90%.
Other ACC/AHA Class IIa indications in asymptomatic
patients include chronic severe primary MR with preserved
LV function in the presence of atrial ﬁbrillation and/or
pulmonary artery systolic pressure greater than 50mmHg at
rest or greater than 60mmHg with exercise. The only Class
I indications for MV repair in asymptomatic patients with
severe primary MR is the presence of LV dysfunction and/or
end-systolic dimension >55mm3 that is patients in phase II
or more of the disease.
The role of conventional surgery for patients with severe
secondary MR, as compared to primary MR, is by far less
well-deﬁned,anditsoutcomeislesspredictable(seeTable 1).
Indications and type of intervention for secondary ischemic
mitral regurgitation, for example, remain open to debate
[6, 12–14]. Some centers report high rates of success using a
simple reduction annuloplasty technique in all patients with
ischemic MR [12], others showed that treatment of ischemic
MR using reduction annuloplasty alone may be incomplete
and suggest that valve replacement may be a better option [6,
14]. The frequency and severity of MR recurrence following
reduction annuloplasty are inﬂuenced by the success of
associated myocardial revascularisation procedures and by
the extent of LV remodeling postoperatively. Repair or
replacement of non-ischemic secondary mitral regurgitation
isemergingasapotentialtherapeuticoptioninthesepatients
[12–14].
4.1. Surgery for Mitral Regurgitation
4.1.1. Valve Repair. Mitral valve repair is easy to do, but
diﬃcult to master. Most of the techniques are well described
in the surgical literature [8, 15, 16], yet achieving consistent,ISRN Cardiology 3
Table 1: Classiﬁcation of and Current Indications for Intervention for Ischemic and Asymptomatic Degenerative MR.
Phase 1
(Normal LV function
and dimensions)
Phase 2
(Normal EF (≥50%)
and ESD with indirect
signs of LV
Dysfunction∗
Phase 3
(EF ≥30%–<50%
and/or mild to
moderate LV
dilatation “ESD >
40mm–55 < mm”)
Phase 4
(EF < 30% and/or
severe LV dilatation
“ESD ≥ 55mm”)
Stage A Mild MR
(ERO < 20mm)
C l a s sI I If o rI s c h e m i c
and Degenerative MR
C l a s sI I If o rI s c h e m i c
and Degenerative MR
Class III for Ischemic
and Degenerative MR
Class III for Ischemic
and Degenerative MR
Stage B Moderate MR
(ERO = 20–39mm)
C l a s sI I af o rI s c h e m i c
and Class III for
Degenerative MR
C l a s sI I af o rI s c h e m i c ,
and Class III for
Degenerative MR
C l a s sI I af o rI s c h e m i c
and Class III for
Degenerative MR
Class IIa for Ischemic
and Class III for
Degenerative MR
Stage C Severe MR
(ERO ≥ 40mm)
Class I for Ischemic
and IIb for
Degenerative MR
C l a s sIf o rI s c h e m i c ,
and IIa for
Degenerative MR
C l a s sIf o rI s c h e m i c
and Degenerative MR
Class IIa for Ischemic
and IIb for
Degenerative MR
Please note:
1Surgery for Ischemic MR is often combined with coronary revascularization.
2For indications of surgery in symptomatic degenerative MR and DCM please see text.
3Successful mitral repair is expected in >90% of asymptomatic severe MR referred for surgery.
∗Indirect signs of LV decompensation may include recent-onset atrial ﬁbrillation, pulmonary artery systolic pressure greater than 50mmHg at rest or greater
than 60mmHg with exercise.
durable repair in more than 90% of cases requires direct and
adequate “hands-on” training. Such an experience can only
be achieved through training programs, master classes and
workshops dedicated to mitral valve repair.
Leaﬂet reconstruction may require resection of the
prolapsingscallop(s),slidingplasty,chordaltransfer,implan-
tation of artiﬁcial chord(s), and accurate sizing of the
annuloplasty ring. Successful outcome of quadrangular or
triangular resection, with or without sliding leaﬂet plasty, is
more predictable when applied to scallop(s) of the posterior
as opposed to the anterior leaﬂet [15–17]. Implantation
of artiﬁcial chords is challenging only in gauging the
appropriate length. It is generally accepted that remodeling
annuloplasty is an essential step in a successful and durable
mitral valve repair. This can be achieved by implantation
of an artiﬁcial ring, designed to restore the natural size
and shape of the annulus. The most commonly used ring
for MV annuloplasty is a semirigid ﬂat ring [8, 17, 18].
A saddle-shaped annuloplasty ring that mimics the 3-D
d y n a m i cn a t u r eo fan o r m a lm i t r a lv a l v ea n n u l u sr e c e n t l y
has been reported to provide superior uniform annular force
distribution compared to ﬂat rings [18]. The ring size is
based on the true size of the anterior mitral valve leaﬂet that
can be derived from the intercommissural distance and the
height of the anterior leaﬂet.
Bileaﬂet reconstruction of a Barlow valve, with marked
redundancyofbothleaﬂets,istime-consumingandprobably
the most challenging valve repair [8, 15–17]. However, this
repair can be achieved by reducing the posterior annular
diameter, limiting the posterior leaﬂet height to less than
1.5cm; combined with anterior leaﬂet reconstruction to
achieve a minimum coaptation distance of 6–8mm, and
adequate sizing of an artiﬁcial mitral valve ring to avoid
systolic anterior motion of the mitral valve apparatus.
Durability of repairing rheumatic mitral valves has proved to
beelusivetomanysurgeons,despiteafewreportsofexcellent
long-term results [19, 20].
5. Mitral Valve Replacement
Even in the best-case scenario, not all mitral valves are
amenable to successful repair. In general, valves with a
lower likelihood for durable repair include those aﬀected by
rheumatic disease with signiﬁcant leaﬂet and/or subvalvular
sclerosis and calciﬁcation. Similarly, mitral valves with sub-
stantial tissue destruction following infective endocarditis;
and some complex myxomatous valves are best treated with
mitral valve replacement. When mitral valve replacement
is required instead of mitral valve repair, preservation of
chordal structures is of substantial importance in order to
preserve ventricular-annular continuity and prevent pro-
gressive postoperative LV dilatation. A number of surgical
techniques for preservation of the posterior and the anterior
l e a ﬂ e t sh a v eb e e np r o p o s e d[ 21, 22].
5.1. Intraoperative Assessment of Mitral Valve. The severity of
MR often is dramatically reduced on IOTEE compared with
preoperative imaging [23], probably as a result of the inﬂu-
enceofgeneralanesthesiaonloadingconditions[24].There-
fore, prepump IOTEE is not ideal for the determination of
MR severity and the need for intervention, especially in the
setting of functional MR. However, increasing pulmonary
capillary wedge to 15 to 18mmHg by rapid ﬂuid infusion
through the aortic cannula, combined with an afterload
challengeusingintravenousphenylephrinetoachieveamean
arterial pressure of ≥100mmHg, may mitigate the eﬀects
of general anesthesia on MR severity. This intraoperative
hemodynamictesthasbeenproposedasaguidetodetermine
whether concomitant repair of secondary ischaemic MR at
the time of surgical coronary revascularization should be
used in patients with mild-to-moderate MR on pre-pump
IOTEE [23–25].
After valve repair and discontinuation of the extracor-
poral circulation, mitral valve is reassessed anatomically
(including diastolic leaﬂetexcursion, adequacyofthe systolic4 ISRN Cardiology
zone of leaﬂet coaptation) as well as functionally (including
severity and mechanism of any residual MR, evidence of
mitral stenosis, and evidence of dynamic subvalvular LV
outﬂow obstruction) [26]. Ventricular function and the
results of any concomitant surgical procedures may also be
assessed.
6. Outcome of Surgery for Mitral Regurgitation
Earlier reports of excellent early and midterm results of
primary mitral valve repair (MVR) [8, 17, 19, 27]m a yh a v e
prohibited the notion of prospective randomized studies
comparing MVR to valve replacement. Mohty et al. [28]
reported the outcome of MVR versus replacement for
isolated MR due to prolapse in 917 patients who had surgery
between 1985 and 1995. The 5-, 10-, and 15-years survival
was 86 ± 1%, 68 ± 2%, and 37 ± 5% of patients who had
mitral valve repair as compared to 71 ± 3%, 49 ± 3%, and
29±4% of those who had mitral valve replacement. Gillinov
etal.[29]havereportedtheshort-andlong-termoutcomein
patients who underwent MV repair or replacement between
1973 and 1999 for degenerative and ischemic heart disease.
The overall survival at 30 days, 1, 5, and 10 years was 97%,
92%, 79%, and 59% after repair and 94%, 88%, 70%, and
37% after replacement. The survival beneﬁt of repair may be
apparent as early as one month after surgery [28].
The relative success of undersizing mitral annuloplasty
in ischemic MR [30] has encouraged Bach and Bolling
[31] to test the same concept in 16 patients with stage
C non-ischemic secondary MR. The excellent results in
terms of low operative mortality, improvement in patients
symptoms,andimprovedventricularfunctionhavealsobeen
reportedbyothers[32].Long-termfollowupofthesestudies,
however, failed to show survival beneﬁt of isolated reduction
annuloplastyforseveresecondaryMRwithstageIII-IVheart
failure [33]. Moreover, recurrence of MR has been reported
to be as high as 30% of survivors [34]. Understanding
the underlying mechanism of secondary MR may explain
why is the eﬀect of undersizing of the mitral annulus on
ventricular function is short lived. Ventricular remodelling is
associatedwithincreaseoftheinterpapillarymuscledistance,
leaﬂet tethering, and reduction in the closing force over
and above annular dilatation [35]. Reversal of ventricular
remodelling by reduction of the LV sphericity index and near
normalisation of the interpapillary distance, for example,
may enhance the results of surgery in stage B and C of phase
III and IV of secondary mitral valve regurgitation. Therefore,
CoreCap and Coapsys devices were designed to prevent
further ventricular dilatation and oﬀer ventricular support
in diastole. The CoreCap, a biocompatible support jacket
wrapped around the heart to prevent further dilatation,
has been evaluated in a multicentre phase II FDA study
[36, 37]. 193 patients with severe MR had mitral valve repair
(84.2%) or replacement (15.8%). The 1.6% 30-day mortality
and 85.2% 2-year survival were complemented by 0 to 1+
MR in 88.4% of patients after 18-month followup. These
excellent results, which are based on robust clinical and
echocardiographic data, have been attributed to judicious
patient selection. The Coapsys device is under evaluation in
the RESTOR-MV study [38].
A meta-analysis of the outcome of repair versus replace-
ment in 29 studies reported between 1960 and 2005 was
recentlypublished[39].The29studiesw er egr oupedac c or d-
ing to the underlying cause of mitral valve regurgitation
(ischemic, degenerative and myxomatous, rheumatic and
mixed mitral valve disease). The summary odds ratio of
early mortality, comparing replacement to repair, was 2.24
(95% conﬁdence interval = 1.78–2.80) [39]. The summary
total survival hazard ratio, comparing replacement to repair,
was 1.58 (95% conﬁdence interval = 1.41–1.78), indicating a
worse outcome amongst patients undergoing valve replace-
ment. The risk of thromboembolic complications was lower
in patients undergoing valve repair (summary hazards ration
= 1.86, replacement versus repair). Surprisingly, the need
for reoperation was not signiﬁcantly diﬀerent between both
groups. Despite the fact that repair for severe ischemic mitral
was beneﬁcial at 30 days, there was no statistically signiﬁcant
inﬂuence on the long-term survival if compared to valve
replacement [39, 40]. These studies suggest that MV repair is
the operation of choice when the valve is suitable for repair.
Case selection and surgical expertise, however, are the most
important determinants of MV repair success and durability.
7. Less InvasiveInterventionsfor
MitralRegurgitation
Along with the use of minimally invasive surgical techniques
for mitral valve surgery [41, 42], several percutaneous
therapies for mitral valve repair also are being investigated
[43–45]. The surgical edge-to-edge mitral repair technique,
also referred to as an Alﬁeri stitch [42], can be emulated
using a percutaneous approach [43–45]. The technique
involves anchoring the free edge of the posterior leaﬂet to
the free edge of the anterior leaﬂet, resulting in a “double-
oriﬁce” or “bow-tie oriﬁce” valve. Using a percutaneous
approach that uses suction to stabilize the valve leaﬂets, a
catheter-based device is deployed to clip together the free
edges of the anterior or posterior leaﬂets under combined
echocardiographic and ﬂuoroscopic guidance. At present, at
least two devices are under investigation for percutaneous
edge-to-edge mitral valve repair: the Mitra-Clip (Evalve Inc,
RedwoodCity,CA)andtheMobiusII(EdwardslifeSciences,
Irvine, CA) [44, 45]. In preliminary results, the Mitra-Clip
was associated with a statistically signiﬁcant reduction in
MR severity among patients in whom the device could be
implanted; however, there were signiﬁcant complications
during and after the procedure, and although diminished in
severity, MR often remained of hemodynamic signiﬁcance
[44, 45].
Other alternative percutaneous techniques for mitral
valve repair include devices placed in and applying traction
to the coronary sinus in an attempt to reduce its circum-
ference, emulating posterior mitral annuloplasty [46], and
other experimental percutaneous devices includes placation
of the LV lateral wall to diminish the eﬀects of mitral leaﬂet
tethering after a posterolateral infarct [47].ISRN Cardiology 5
Dramatically diminished post-procedure MR severity
and longer-term followup are required before considering
transcatheter edge-to-edge repair as a realistic therapeutic
option for MR. Concerns regarding the long-term outcome
of isolated edge-to-edge repair arise from the lack of asso-
ciated mitral annuloplasty; surgical Alﬁeri repair typically is
supplemented with implantation of a synthetic annuloplasty
ring that was required in 93% of cases in one report [42].
Furthermore, experimental studies showed increased degree
oftensionattheleveloftheAlﬁeristitch,coupledwithhigher
diastolic leaﬂet stresses due to persistent and/or progressive
mitral annular dilatation and may lead to recurrence of MR
[48]. These ﬁndings suggest that concomitant mitral ring
annuloplasty may be necessary to achieve satisfactory long-
tem results after Alﬁeri repair. However, because more than
30% of patients with severe MR might not undergo surgery
due to associated comorbidities [49], the availability of a
less invasive procedure—even with palliative intent alone—
could be a welcome addition to the existing armamentarium
for managing severe MR.
8. Summary
Severe MR is associated with signiﬁcant morbidity and
mortality. Repair or replacement is recommended for symp-
tomatic patients with or without signs of LV dysfunction,
and in asymptomatic patients with LV enlargement, sys-
tolic dysfunction, pulmonary hypertension, or new atrial
ﬁbrillation. Valve repair (with >90% likelihood of successful
repair) may be recommended in asymptomatic patients with
severe primary MR even in the absence of LV dysfunction.
Mitral valve repair may oﬀer survival beneﬁt over mitral
valvereplacementandshouldbeconsideredtheprocedureof
choice for patients who require intervention. Pre-operative
testing typically relies on echocardiography/Doppler imag-
ing, often including TEE. Intraoperative TEE is an important
adjunct to surgical intervention for MR, in part addressing
the adequacy of repair and need for revision or valve
replacement. Percutaneous therapies are under development
and may increase the number and type of patients who
stand to beneﬁt from intervention. At present, the state-of-
the art management of severe MR requires understanding
its etiology and suitability of the valve for repair, and
appropriately timing referral for intervention in the context
of the patient, the presence of symptoms, evidence of LV
dilation or dysfunction, and likelihood of successful repair.
The classiﬁcation provided may help in deciding if and when
to intervene in patients with severe ischemic or degenerative
MR.
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